Related Experiment Video
Updated: Aug 14, 2026
05:51
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Pharmacogenomics: a path to predictive medicine for schizophrenia
Simone Gupta1, Sanjeev Jain, Samir K Brahmachari
1Institute of Genomics and Integrative Biology (CSIR), Delhi University Campus, Delhi 110007, India.
Pharmacogenomics
|December 16, 2005
Summary
Pharmacogenetics can predict antipsychotic drug response in schizophrenia by examining genes involved in neurotransmitter systems. This personalized medicine approach requires validating genetic markers with large patient sample data.
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Patient response to antipsychotics varies significantly due to multiple factors.
- Schizophrenia's complex etiology involves intricate symptom interactions.
Purpose of the Study:
- To review the association between pharmacogenetics and antipsychotic drug response in schizophrenia.
- To highlight the potential of pharmacogenomics for predicting treatment outcomes.
Main Methods:
- Literature review of pharmacogenetic associations with schizophrenia.
- Presentation of a network model for neurotransmitter signaling systems.
Main Results:
- Pharmacogenomics offers a unique approach to predict antipsychotic response by investigating genes linked to specific symptoms and side effects.
- Genes involved in molecular mechanisms of schizophrenia and drug response are potential susceptibility genes and drug targets.
Conclusions:
- Experimental validation of genes in neurotransmitter systems and large, well-phenotyped patient samples are crucial for identifying reliable biomarkers.
- Integrating genetic polymorphisms with clinical response data will advance personalized medicine for schizophrenia treatment.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...